不一样的风采:聚焦2017eyeforpharma巴塞罗那大会

2017-03-15 MedSci MedSci原创

2107年3月14日,医药届最知名的会议eyeforpharma巴塞罗那大会开始了2天半的日程。1200名来自全球的业内人士聚集在这里,探索医药与医疗产业未来的发展。随着全球最大的医疗保健市场-美国,以及一些新兴市场医保政策的预期趋向保守,以及全球范围内医药行业平均利润率不断走弱,对现有商业模式的思变是一直是这几年eyeforpharma巴塞罗那的声音。相较于前几届较为宏观的、有战略高度的“以患者

2107年3月14日,医药届最知名的会议eyeforpharma巴塞罗那大会开始了2天半的日程。1200名来自全球的业内人士聚集在这里,探索医药与医疗产业未来的发展。

随着全球最大的医疗保健市场-美国,以及一些新兴市场医保政策的预期趋向保守,以及全球范围内医药行业平均利润率不断走弱,对现有商业模式的思变是一直是这几年eyeforpharma巴塞罗那的声音。相较于前几届较为宏观的、有战略高度的“以患者为中心”的主题,今年大会主题似乎更接地气,“United for healthcare. Driven by outcomes”,大会第一天演讲听到最多的关键词就是“outcomes”,“outcomes”成为衡量药企从宏观战略到具体产品,从药物研发到市场营销全方位的一个标杆。

RWE作为展示价值(demonstrate value)、挖掘实效(achieve research outcomes)的关键能力被多次提及。制药企业如何建立并有效利用RWE生态体系也成为探讨的热点。

本届eyeforpharma巴塞罗那大会有1200名参会代表,来自:药企、医疗器械公司、政府、协会、CRO、保险公司、HMO、VC、医疗机构、患者组织、科研院所和高效、公益慈善组织、患者社区等;78个国际制药企业参与;105位演讲嘉宾。

eyeforpharma 是一家专注于医药企业、患者组织、医疗健康等领域的咨询机构。eyeforpharma 定期邀请全球医药行业精英来探讨医药行业发展的最新趋势和前沿动态。 




版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908230, encodeId=ef43190823078, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 31 05:11:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787218, encodeId=e1c51e87218d9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 22 02:11:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029816, encodeId=923f202981689, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Dec 28 23:11:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181152, encodeId=c9b618115215, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/83250355f722e239b901c41df857f569.jpg, createdBy=7d5c2038722, createdName=1821e930b2m, createdTime=Sun Mar 19 15:20:46 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180373, encodeId=4e251803e3c6, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Mar 16 17:51:57 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180143, encodeId=5d22180143c6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85172002258, createdName=珍珍superwoman, createdTime=Wed Mar 15 21:58:10 CST 2017, time=2017-03-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908230, encodeId=ef43190823078, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 31 05:11:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787218, encodeId=e1c51e87218d9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 22 02:11:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029816, encodeId=923f202981689, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Dec 28 23:11:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181152, encodeId=c9b618115215, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/83250355f722e239b901c41df857f569.jpg, createdBy=7d5c2038722, createdName=1821e930b2m, createdTime=Sun Mar 19 15:20:46 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180373, encodeId=4e251803e3c6, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Mar 16 17:51:57 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180143, encodeId=5d22180143c6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85172002258, createdName=珍珍superwoman, createdTime=Wed Mar 15 21:58:10 CST 2017, time=2017-03-15, status=1, ipAttribution=)]
    2017-08-22 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908230, encodeId=ef43190823078, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 31 05:11:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787218, encodeId=e1c51e87218d9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 22 02:11:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029816, encodeId=923f202981689, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Dec 28 23:11:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181152, encodeId=c9b618115215, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/83250355f722e239b901c41df857f569.jpg, createdBy=7d5c2038722, createdName=1821e930b2m, createdTime=Sun Mar 19 15:20:46 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180373, encodeId=4e251803e3c6, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Mar 16 17:51:57 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180143, encodeId=5d22180143c6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85172002258, createdName=珍珍superwoman, createdTime=Wed Mar 15 21:58:10 CST 2017, time=2017-03-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908230, encodeId=ef43190823078, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 31 05:11:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787218, encodeId=e1c51e87218d9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 22 02:11:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029816, encodeId=923f202981689, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Dec 28 23:11:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181152, encodeId=c9b618115215, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/83250355f722e239b901c41df857f569.jpg, createdBy=7d5c2038722, createdName=1821e930b2m, createdTime=Sun Mar 19 15:20:46 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180373, encodeId=4e251803e3c6, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Mar 16 17:51:57 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180143, encodeId=5d22180143c6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85172002258, createdName=珍珍superwoman, createdTime=Wed Mar 15 21:58:10 CST 2017, time=2017-03-15, status=1, ipAttribution=)]
    2017-03-19 1821e930b2m

    棒棒哒

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1908230, encodeId=ef43190823078, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 31 05:11:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787218, encodeId=e1c51e87218d9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 22 02:11:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029816, encodeId=923f202981689, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Dec 28 23:11:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181152, encodeId=c9b618115215, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/83250355f722e239b901c41df857f569.jpg, createdBy=7d5c2038722, createdName=1821e930b2m, createdTime=Sun Mar 19 15:20:46 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180373, encodeId=4e251803e3c6, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Mar 16 17:51:57 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180143, encodeId=5d22180143c6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85172002258, createdName=珍珍superwoman, createdTime=Wed Mar 15 21:58:10 CST 2017, time=2017-03-15, status=1, ipAttribution=)]
    2017-03-16 wxl882001

    学习一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1908230, encodeId=ef43190823078, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 31 05:11:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787218, encodeId=e1c51e87218d9, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Aug 22 02:11:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029816, encodeId=923f202981689, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Thu Dec 28 23:11:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181152, encodeId=c9b618115215, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/19/83250355f722e239b901c41df857f569.jpg, createdBy=7d5c2038722, createdName=1821e930b2m, createdTime=Sun Mar 19 15:20:46 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180373, encodeId=4e251803e3c6, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Mar 16 17:51:57 CST 2017, time=2017-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180143, encodeId=5d22180143c6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85172002258, createdName=珍珍superwoman, createdTime=Wed Mar 15 21:58:10 CST 2017, time=2017-03-15, status=1, ipAttribution=)]
    2017-03-15 珍珍superwoman

    学习了

    0

相关资讯

两会专题:全国人大代表“医疗健康”领域议案汇总

3月3日,第十二届全国人民代表大会第五次会议在北京开幕。药品审评审批、消除审批积压、药品价格合规等再度成为全国人大代表关注的焦点。

2017年全国两会 “医疗领域”看什么?

又到一年一度全国“两会”时,而“两会”上所传达出来的信息,上至国家战略下至百姓民生,更是成为了社会发展风向标,无不与我们的生活息息相关。有媒体预测医疗、楼市、税务、儿童、教育、共享经济、供给侧改革、扶贫、宗教等九大热点将是2017年两会热门议题。全国两会“医疗领域”看什么?3月2日,在全国政协十二届五次会议新闻发布会上,新闻发言人王国庆回答了中外记者的提问。他就经济问题、扶贫问题、三农问题、南海问

医疗领域几多坑!百度医生4月1日将彻底关停

图片来自“123rf.com.cn”今日百度医生公众号推送了一则消息——《百度医生关停公告》,宣布因“公司业务调整,百度医生将关停服务并下线”。据公开信息显示,百度医生移动网页版于2014年10月上线,App版于2015年1月正式上线,可以提供预约医生、智能导诊、精准搜索、多选医生、就诊评价等五个模块的服务。截至亿欧发稿时,打开百度医生的网页端依旧能看到:全国已开通343个城市、12862个医院,

人工智能显神通 罕见病新疗法已在不远方

罕见病又称为孤儿病,指的是仅发生在极少数人身上的疾病,例如杜氏肌营养不良症 (Duchenne Muscular Dystrophy) 和囊性纤维化(Cystic Fibrosis)。这些疾病大多为遗传病,虽然单独一种罕见病影响到的患者人数不多,但是罕见病的种类却一点也不少。目前将近有七千种罕见病被发现,加在一起,它们影响到很多人的生活。据估计在美国就有三千万罕见病患者。由于罕见病影响的人群数量较

医疗领域的又一次革命:科学家成功研发在你体内监测健康的胶囊

近日,科学家成功研发了可通过自身胃液驱动的胶囊,能够在身体内部向你手机发送健康数据。通过持续不断的监测你的健康和服药情况,这个微型的胶囊将会掀起医疗领域的又一次革命。来自麻省理工大学的科研教授 Phillip Nadeau 表示:“这款自驱动的胶囊在服用后,能够在你身体内持续数周监测各种生理指标。它会固定在胃里,进行各种指标测量并将其传输至你的手机中。”在美国波士顿举行的全球最大生物峰会上,Nad

“中国巴菲特”郭广昌:两会医疗提案关注啥

2017年全国两会正在进行。3月3日,第十二届全国政协委员、被称为“中国巴菲特”的郭广昌再次提交了两份关注医疗领域的提案。这两份提案分别是“关于鼓励建设以健康为中心的科创综合体的提案”以及“关于加快建设医学人工智能支撑体系的提案”。郭广昌建议制定相关政策,鼓励大型生物医药企业集团建设以健康为中心的科创综合体,发挥在创新领域的引领示范作用,培育出一批具有国际影响力的以“健康”为中心、“创新”为导向的